دورية أكاديمية
أعرض في EDS

Is intravenous valproate more efficacious than oral valproate for inpatients with bipolar I disorder with a manic or depressive episode and concomitant symptoms of opposite polarity?

التفاصيل البيبلوغرافية
العنوان: Is intravenous valproate more efficacious than oral valproate for inpatients with bipolar I disorder with a manic or depressive episode and concomitant symptoms of opposite polarity?
المؤلفون: Cuomo A; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy., Barillà G; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy., Cattolico M; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy., Carmellini P; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy., Spiti A; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy., Pozza A; Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy., Fagiolini A; Department of Molecular and Developmental Medicine, Division of Psychiatry, University of Siena, Siena, Italy.
المصدر: Bipolar disorders [Bipolar Disord] 2024 May; Vol. 26 (3), pp. 277-283. Date of Electronic Publication: 2023 Nov 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Munksgaard Country of Publication: Denmark NLM ID: 100883596 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1399-5618 (Electronic) Linking ISSN: 13985647 NLM ISO Abbreviation: Bipolar Disord Subsets: MEDLINE
أسماء مطبوعة: Publication: Copenhagen : Wiley-Blackwell Munksgaard
Original Publication: Copenhagen, Denmark : Munksgaard, 1999-
مواضيع طبية MeSH: Valproic Acid*/administration & dosage , Valproic Acid*/therapeutic use , Bipolar Disorder*/drug therapy , Antimanic Agents*/administration & dosage , Antimanic Agents*/therapeutic use , Psychiatric Status Rating Scales* , Inpatients* , Administration, Intravenous*, Humans ; Female ; Male ; Adult ; Administration, Oral ; Retrospective Studies ; Middle Aged ; Treatment Outcome ; Young Adult ; Mania/drug therapy
مستخلص: Intro: Valproic acid (VPA) is a commonly prescribed mood stabilizer, available in both oral (OS) and intravenous (IV) formulations. However, few studies have compared their safety and efficacy. This retrospective study aimed to investigate the safety and efficacy of and IV-VPA in patients with Bipolar Disorder.
Methods: Fifty patients with Bipolar Disorder experiencing a manic or depressive episode, with concomitant symptoms of opposite polarity, admitted to our inpatient unit and treated with IV-VPA were included in a retrospective, single-centre, non-randomized, open-label, parallel-group comparative study. Fifty patients experiencing a manic or depressive episode, with concomitant symptoms of opposite polarity, treated with oral-VPA and selected among those who were admitted to the inpatient unit prior to the introduction of IV-VPA in our clinical practice, were included as the control group (matched based on age, gender and clinical scales score at baseline). The Clinical Global Impression (CGI), Young Mania Rating Scale (YMRS), Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A) scores were recorded at baseline, after 3 days of treatment and discharge from the inpatient unit. Patients were asked to respond on the basis of the symptoms present on the day the scale was administered. Response rate and the presence of adverse effects were also recorded.
Results: Both patients treated with oral and IV-VPA demonstrated significant improvements in all psychometric scales (p < 0.001). However, the IV group exhibited superior efficacy, with significantly lower scores on the CGI, YMRS, MADRS and HAM-A scales on Day 3 and at discharge from the inpatient unit. The IV-VPA treatment showed higher response rates on all psychometric scales, and no adverse effects were reported in either group.
Conclusion: This retrospective study supports the use of IV-VPA as a more efficacious treatment option for patients with Bipolar Disorder, particularly in acute settings where rapid symptom improvement is crucial. Both oral and IV-VPA were found to be safe and well-tolerated.
(© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
References: Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet Lond Engl. 2016;387(10027):1561‐1572.
Yatham LN, Chakrabarty T, Bond DJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord. 2021;23(8):767‐788.
Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo‐controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006;67(10):1501‐1510.
Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. 2013;2013(10):CD003196.
Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro‐Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP‐BD‐2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20(2):180‐195.
Norton JW, Quarles E. Intravenous valproate in neuropsychiatry. Pharmacotherapy. 2000;20(1):88‐92.
Fontana E, Mandolini GM, Delvecchio G, Bressi C, Soares JC, Brambilla P. Intravenous valproate in the treatment of acute manic episode in bipolar disorder: a review. J Affect Disord. 2020;260:738‐743.
Olivola M, Civardi S, Damiani S, et al. Effectiveness and safety of intravenous valproate in agitation: a systematic review. Psychopharmacology (Berl). 2022;239(2):339‐350.
Meehan K, Zhang F, David S, et al. A double‐blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389‐397.
Chengappa KNR, Kupfer DJ, Frank E, et al. Relationship of birth cohort and early age at onset of illness in a bipolar disorder case registry. Am J Psychiatry. 2003;160(9):1636‐1642.
Rosa AR, Singh N, Whitaker E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain‐derived neurotrophic factor (BDNF) levels. Psychol Med. 2014;44(11):2409‐2418.
Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet Lond Engl. 2013;381(9878):1672‐1682.
Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primer. 2018;4:18008.
Busner J, Targum SD. The clinical global impressions scale. Psychiatry Edgmont. 2007;4(7):28‐37.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci. 1978;133:429‐435.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382‐389.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56‐62.
Ghaleiha A, Haghighi M, Sharifmehr M, et al. Oral loading of sodium valproate compared to intravenous loading and oral maintenance in acutely manic bipolar patients. Neuropsychobiology. 2014;70(1):29‐35.
Sekhar S, Kalra B, Mendhekar DN, Tekur U. Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open‐label comparative study. J Clin Pharmacol. 2010;50(6):688‐692.
فهرسة مساهمة: Keywords: bipolar disorder; psychopharmacology; valproic acid
المشرفين على المادة: 614OI1Z5WI (Valproic Acid)
0 (Antimanic Agents)
تواريخ الأحداث: Date Created: 20231114 Date Completed: 20240514 Latest Revision: 20240514
رمز التحديث: 20240514
DOI: 10.1111/bdi.13388
PMID: 37957926
قاعدة البيانات: MEDLINE
الوصف
تدمد:1399-5618
DOI:10.1111/bdi.13388